NEW YORK--(BUSINESS WIRE)--July 09, 2025-- 
 
   SK Capital Partners, LP ("SK Capital"), a New York-based private 
investment firm focused on the specialty materials, ingredients, and 
life sciences sectors, today announced that its affiliate has entered 
into exclusive negotiations with LISI Group (Euronext: FII) to acquire 
LISI Group's Medical division ("Lisi Medical" or the "Company"). 
 
 
   The transaction remains subject to the approval of the competent 
antitrust authorities, foreign direct investment control authorities and 
to the information and consultation processes of the relevant employee 
representative bodies in accordance with applicable laws. As such, the 
transaction is expected to close in the second half of 2025. 
 
 
   Lisi Medical is a leading MedTech CDMO focused on the production of 
high-precision metal components and assemblies serving global medical 
device original equipment manufacturers ("OEMs"). The Company's products 
include instruments utilized in minimally invasive and robotic-assisted 
surgery as well as orthopedic implants. Lisi Medical operates four 
manufacturing sites with expertise in precision machining, forging, and 
engineering solutions, including highly automated production -- two in 
Minnesota, U.S. and two in France. 
 
 
   Josh Lieberman, Principal at SK Capital, commented, "We feel privileged 
to partner with LISI Group to acquire Lisi Medical, whose deep 
engineering heritage and cutting-edge manufacturing technologies enable 
it to serve as a critical solutions provider for the world's largest 
MedTech OEM customers. Under LISI Group's ownership, the Company has 
made significant investments to increase automation, expand production 
capacity, and add capabilities to support the growth of its customers. 
We look forward to working with Lisi Medical's management team to 
accelerate the Company's growth by expanding with existing and new 
customers and continuing to add new capabilities both organically and 
through M&A." 
 
 
   Aaron Davenport, Managing Director at SK Capital, added, "Given Lisi 
Medical's highly engineered solutions and deep relationships with 
leading MedTech customers, the Company fits very well within the SK 
Capital portfolio. SK Capital has deep experience in the life sciences 
CDMO sector and a long-standing track record of carving out businesses 
and establishing them as thriving, independent platforms, and we believe 
Lisi Medical represents an attractive opportunity to implement our 
transformational growth strategy." 
 
 
   Emmanuel Viellard, CEO of LISI Group, stated, "After 14 years of strong 
development and manufacturing consolidation within LISI Group, we are 
now looking forward to partner with SK Capital and boost Lisi Medical's 
next development phase. Their strong track record in the life sciences 
sector and proven experience in France provide the essential strategic 
foresight and financial power to support the company going forward. This 
will also empower Lisi Medical to expand its offerings and capabilities, 
while solidifying its standing as a top-tier partner for leading MedTech 
OEMs. We are confident this transaction will be beneficial to all 
stakeholders of Lisi Medical, be it employees, clients or suppliers." 
 
 
   Kirkland & Ellis is serving as legal counsel and Piper Sandler & Co., 
Jefferies LLC, and Sycomore Corporate Finance are serving as financial 
advisors to SK Capital. Partners Group, acting on behalf of its clients, 
provided committed debt financing in support of the transaction. 
 
 
   Rothschild & Co is serving as financial advisor and Dentons is serving 
as legal counsel to LISI Group. 
 
 
   About SK Capital 
 
 
   SK Capital is a transformational private investment firm with a 
disciplined focus on the specialty materials, ingredients, and life 
sciences sectors. The firm seeks to build resilient, sustainable, and 
growing businesses that create substantial long-term value. SK Capital 
aims to utilize its industry, operating, and investment experience to 
identify opportunities to transform businesses into higher performing 
organizations with improved strategic positioning, growth, and 
profitability, as well as lower operating risk. SK Capital currently has 
approximately $10 billion in assets under management as of December 31, 
2024. For more information, please visit www.skcapitalpartners.com. 
 
 
   About the LISI Group 
 
 
   LISI is a global industrial group specialising in the manufacture of 
high value-added assembly solutions and components for the aerospace, 
automotive and medical sectors. As a partner to the world's leading 
players and driven by its long-standing family values, LISI innovates 
and invests in research and development for the products of tomorrow. to 
meet its customers' needs, particularly in terms of quality, safety and 
performance. The LISI Group thus sets itself apart by relying on two 
strategic pillars: innovation and operational excellence, while 
integrating a strong CSR culture. Learn more at www.lisi-group.com. 
 
 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250709076615/en/

 
 
    CONTACT:    Jeremy Milner 
 
   Gregory FCA 
 
   jmilner@gregoryfca.com 
 
 
   (401) 862-9422 
 
 
 
 
 
 

(END) Dow Jones Newswires

July 09, 2025 11:49 ET (15:49 GMT)